Section to complete information about primary and secondary outcomes including. It includes the metric or method of measurement used and, the time point for every outcome.
Primary outcome(s):
Percentage reduction in the IBS-SS (Francis) questionnaire score: (To determine the percentage reduction, the change in the total score obtained from the IBS-SS (Francis) questionnaire at week 12 of treatment will be evaluated relative to the baseline value. An individual response will be considered to have occurred if the percentage reduction at 12 weeks (V3) compared to the baseline value (V0) is 30% or greater. Two intermediate assessments are included to determine when a response to treatment first becomes evident and how that response evolves over time.)
Key secondary outcomes:
Related to efficacy:
1. Reduction in the IBS-SS (Francis) questionnaire score: (The difference between the total score on the IBS-SS (Francis) questionnaire at the end of the 12-week treatment period and the baseline score will be evaluated. A reduction of at least 50 points in the total score will be considered for the assessment of this secondary efficacy endpoint. Two interim assessments are included to determine when clinical improvement begins to manifest and how it progresses over time.)
2. Improvement in Irritable Bowel Syndrome (IBS) severity: (IBS severity will be assessed using an IBS severity classification based on the total scale score: normal: 0 to < 75; mild: ≥ 75 to < 175; moderate: ≥ 175 to ≤ 300; severe: > 300. An improvement in severity will be considered to have occurred if, by week 12, the initial severity classification has decreased by at least one level.)
3. Pain intensity (change in the value for this variable from the IBS-SS (Francis) questionnaire at the end of treatment compared to the baseline value). Measurement time points: baseline, weeks 2, 4, and 12, and week 14 (follow-up).
4. Intensity of abdominal distension: change in the value for this variable from the IBS-SS (Francis) questionnaire at the end of treatment compared to the baseline value. Measurement time points: baseline, weeks 2, 4, 12, and week 14 (follow-up)
5. Changes in bowel habits (Change in the score for this variable from the IBSSS questionnaire (Francis) at the end of treatment compared to the baseline value). Measurement time points: baseline, weeks 2, 4, 12, and week 14 (follow-up)
6. Quality of Life: (IBS-QOL questionnaire). Measurement time points: at baseline, week 12
Safety-related:
7. Adverse events (AEs) (Incidence of AEs reported by the patient or via laboratory tests, measured as: Occurrence of an AE (Yes, No); Description of the AE (name of the adverse event); Duration of the AE (difference in dates between the onset and resolution of the AE); Intensity of the AE (mild, moderate, severe, life-threatening or disabling AE, or AE resulting in death); Severity of the AE (serious, non-serious); Action taken regarding the study treatment (no change, dose modification, temporary or permanent discontinuation of the study treatment); Outcome of the AE (recovered, improved, persistent, or sequelae); Causal relationship (1. Definite, 2. Highly probable, 3. Probable, 4. Possible, 5. Unrelated, 6. Unknown)). Measurement time points: at baseline, weeks 2, 4, 12, and week 14 (follow-up).